Invitation: Sobi's Q1 2023 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call. The presentation can be followed livehere  or afterwards onsobi.com. The slides will be made available onsobi.comprior to the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031 United Kingdom : +44 207 107 06 13 United States : +1 631 570 56 13 For other...

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please get details here

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Matt Tooth
Global Head of External Communications
[email protected]
+46 73 3133 330

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q1-2023-report-301801668.html